Purification of paraoxonase enzyme from the sera of patients with behcet’s disease and analyzing the effects of the drugs containing imuran (azathioprine), prednisolone (methylprednisolone) and colchium (colchicine)

MakaleYalnız künyeScopus SJRQ2
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

In this study, serum samples from 50 patients with the diagnosis of Behcet’s disease and 20 healthy volunteers were analyzed. The study consists of three parts. In the first part, paraoxonase (PON) activities were determined in the serum samples of 50 patients with Behcet’s disease and 20 healthy people. In the second part, equal volumes of serum samples from 50 patients were pooled and PON enzymes were purified by using Sepharose-4B-L-tyrosine tyrosine-1-naphtylamine affinity column. Optimum temperature, optimum pH, Vmax and Km values of the pure enzymes were determined. The same purification procedure was also performed in the serum samples of 20 healthy people. Electrophoretic mobility was observed (via SDS-PAGE) in the PON enzymes that were purified from the serum samples of patients with Behcet’s disease and healthy people. In the third part, in vitro effects of drugs containing azathioprine, methylprednisolone and colchicine that have already been used for the treatment of Behcet’s disease were tested on the PON enzymes of the patients with Behcet’s disease and control group. IC50 values and Ki constant values were measured and inhibition types were determined for the drugs containing azathioprine, methylprednisolone and colchicine that have already been used for the treatment of the Behcet’s disease and demonstrate in vitro inhibition effects.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/13776Resmi atıflarda kullanılan kalıcı adres
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
2
OpenAlex
3
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorDemir, Nazan
dc.contributor.authorNadaroglu, Hayrunnisa
dc.contributor.authorOzkan, Asuman
dc.contributor.authorTasgin, Esen
dc.contributor.authorIsik, Ceyhun
dc.contributor.authorDemir, Yasar
dc.date.accessioned2026-10-29T19:11:26.517240965Z
dc.date.available2026-10-29T19:11:26.517240965Z
dc.date.issued2014
dc.description.abstractIn this study, serum samples from 50 patients with the diagnosis of Behcet’s disease and 20 healthy volunteers were analyzed. The study consists of three parts. In the first part, paraoxonase (PON) activities were determined in the serum samples of 50 patients with Behcet’s disease and 20 healthy people. In the second part, equal volumes of serum samples from 50 patients were pooled and PON enzymes were purified by using Sepharose-4B-L-tyrosine tyrosine-1-naphtylamine affinity column. Optimum temperature, optimum pH, Vmax and Km values of the pure enzymes were determined. The same purification procedure was also performed in the serum samples of 20 healthy people. Electrophoretic mobility was observed (via SDS-PAGE) in the PON enzymes that were purified from the serum samples of patients with Behcet’s disease and healthy people. In the third part, in vitro effects of drugs containing azathioprine, methylprednisolone and colchicine that have already been used for the treatment of Behcet’s disease were tested on the PON enzymes of the patients with Behcet’s disease and control group. IC50 values and Ki constant values were measured and inhibition types were determined for the drugs containing azathioprine, methylprednisolone and colchicine that have already been used for the treatment of the Behcet’s disease and demonstrate in vitro inhibition effects.
dc.identifier.doi10.2174/1872312808666140514113838
dc.identifier.endpage75
dc.identifier.issn1872-3128
dc.identifier.issue1
dc.identifier.pmid24826966
dc.identifier.scopus2-s2.0-84925443248
dc.identifier.startpage67
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/13776
dc.identifier.volume8
dc.language.isoen
dc.publisherBentham Science Publishers B.V.
dc.relation.ispartofDrug Metabolism Letters
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAzathioprine
dc.subjectBehcet disease
dc.subjectColchicine
dc.subjectMethylprednisolone
dc.subjectParaoxonase
dc.subjectPurification
dc.subject.otherAryldialkylphosphatase
dc.subject.otherAzathioprine
dc.subject.otherBehcet Syndrome
dc.subject.otherCase-Control Studies
dc.subject.otherColchicine
dc.subject.otherEnzyme Inhibitors
dc.subject.otherHumans
dc.subject.otherKinetics
dc.subject.otherMethylprednisolone
dc.subject.otherarylesterase
dc.subject.othersepharose
dc.subject.otherenzyme inhibitor
dc.subject.otherPON1 protein, human
dc.subject.otherArticle
dc.subject.otherBehcet disease
dc.subject.othercontrolled study
dc.subject.otherdrug blood level
dc.subject.otherdrug purification
dc.subject.otherelectrophoretic mobility
dc.subject.otherenzyme assay
dc.subject.otherhuman
dc.subject.otherin vitro study
dc.subject.othermajor clinical study
dc.subject.othermaximum reaction velocity
dc.subject.otherpH
dc.subject.otherpolyacrylamide gel electrophoresis
dc.subject.otherpriority journal
dc.subject.otherprotein determination
dc.subject.othertemperature
dc.subject.otherantagonists and inhibitors
dc.subject.otherblood
dc.subject.othercase control study
dc.subject.otherenzymology
dc.titlePurification of paraoxonase enzyme from the sera of patients with behcet’s disease and analyzing the effects of the drugs containing imuran (azathioprine), prednisolone (methylprednisolone) and colchium (colchicine)
dc.typeArticle
rdl.citation.openalex3
rdl.citation.scopus2
rdl.oa.statusclosed
rdl.scopus.quartileQ2
rdl.sdgSDG03
rdl.source.indexSCOPUS